Tune Therapeutics
Akira Matsuno is the President, Chief Financial Officer, and Co-Founder of Tune Therapeutics.
An accomplished biotech executive with a background in cell & gene therapies, Akira was previously CFO and Head of Corporate Development at Lyell Immunopharma, where he led multiple private fundraising rounds, strategic alliances, and a global R&D collaboration.
Prior to Lyell, he was the global NEX-T Platform Program Lead at Juno Therapeutics, focused on the development of a next-generation cell therapy manufacturing process and multiple drug candidates. As Vice President of Finance, he led the strategic planning, FP&A, and treasury organizations, and led negotiations on multiple executed transactions, including academic partnerships, industry collaborations, and acquisitions. He is also the Co-Founder of JW Therapeutics, a cell therapy company based in China. Across these roles, Akira has executed over $50BN in financing and strategic transactions – including over $2BN in equity-related transactions. Previously, Akira was a late-stage private equity investment professional at Vulcan Capital and started his career at Lehman Brothers, in its investment banking division.
He received his B.S. in Finance and Management from the Wharton School of the University of Pennsylvania.
This person is not in any offices
Tune Therapeutics
1 followers
With its versatile and powerful TEMPO epigenomic control platform, Tune Therapeutics is pioneering a new therapeutic modality that can fine-tune any gene network and unlock the full power and potential of regenerative medicine. With deep experience and a passionate commitment to exploration and innovation, Tune is driving through an inflection point in the history of genetic medicine: from targeting a limited range of rare conditions, to addressing thousands of common and complex diseases for which no curative treatment is available.